Neuronetics, Inc. (NASDAQ:STIM) EVP William Andrew Macan Sells 12,175 Shares

Neuronetics, Inc. (NASDAQ:STIM) EVP William Andrew Macan sold 12,175 shares of Neuronetics stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $3.83, for a total value of $46,630.25. Following the sale, the executive vice president now owns 388,647 shares of the company’s stock, valued at approximately $1,488,518.01. This represents a 3.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

William Andrew Macan also recently made the following trade(s):

• On Monday, February 10th, William Andrew Macan sold 1,970 shares of Neuronetics stock. The shares were sold at an average price of $3.28, for a total value of $6,461.60.

Neuronetics Stock Up 11.8 %

Shares of STIM stock opened at $4.36 on Friday. The stock’s 50 day simple moving average is $2.20 and its 200 day simple moving average is $1.42. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. Neuronetics, Inc. has a twelve month low of $0.52 and a twelve month high of $5.07.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Tradewinds LLC. bought a new position in shares of Neuronetics in the 4th quarter valued at approximately $32,000. XTX Topco Ltd bought a new position in shares of Neuronetics in the 4th quarter valued at approximately $49,000. Landscape Capital Management L.L.C. bought a new position in shares of Neuronetics in the 3rd quarter valued at approximately $53,000. GSA Capital Partners LLP increased its position in Neuronetics by 64.5% in the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after buying an additional 30,837 shares during the period. Finally, David J Yvars Group increased its position in Neuronetics by 47.1% in the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock worth $75,000 after buying an additional 14,825 shares during the period. 53.59% of the stock is owned by institutional investors.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.